JPMorgan analyst Lisa Gill lowered the firm’s price target on UnitedHealth (UNH) to $405 from $525 and keeps an Overweight rating on the shares. The firm updated the company’s estimates following the CEO change and suspension of its 2025 guidance. The analyst believes UnitedHealth has the ability to work on some of the factors that have driven the downward revision, particularly in OptumHealth over the course of 2025 and 2026. With the better than anticipated Medicare Advantage 2026 rates and continued improvement in Medicaid rates, there is still a path to low-double-digit adjusted earnings growth for UnitedHealth, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNH:
- VOO ETF News, 5/15/2025
- UnitedHealth price target lowered to $362 from $513 at Barclays
- UnitedHealth Stock Crashes as DOJ Launches Criminal Medicare Fraud Probe
- Optimistic Buy Rating for UnitedHealth Amid Challenges and Strategic Growth
- UnitedHealth Stock Tanks: Here’s What Oppenheimer Predicts Next